8-K current report · filed Sep 1, 2026

Moderna (MRNA) 8-K Current Report: September 1, 2026

Item 1.01Item 2.03Item 8.01Item EX-99.1Item EX-99.2Item 3.02MRNA overview

Short answer

Moderna (MRNA) filed an 8-K current report with the SEC on September 1, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 3.02 (Unregistered Sales of Equity Securities). $3.0B zero-coupon convertible debt due March 2032, providing substantial funding without regular cash interest.

Moderna 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $3.0B zero-coupon convertible debt due March 2032, providing substantial funding without regular cash interest
  • Net proceeds $2,957.3M, including $328.8M for capped calls and remaining funds for oncology investment or debt repayment
  • Initial conversion price $210.58, a 47.5% premium to Moderna’s $142.77 share price, limiting near-term dilution risk
  • Capped calls cover underlying shares, reducing conversion dilution or excess-cash payments up to a $392.62 cap price
  • Redemption unavailable before September 6, 2029, while conversion could create dilution if shares exceed conversion thresholds

Item 2.03 · Creation of a Direct Financial Obligation

  • Item 2.03 points investors to Item 1.01 for details of any newly created direct financial obligation
  • Financial impact depends on the referenced agreement’s payment obligations, timing, and counterparty terms

Item 3.02 · Unregistered Sales of Equity Securities

  • Convertible notes sold privately under Section 4(a)(2) and Rule 144A, limiting immediate public trading
  • Initial conversion potential: 14,246,100 common shares
  • Maximum conversion potential: 21,012,600 shares in limited circumstances
  • Potential dilution to existing shareholders, subject to customary anti-dilution adjustments
  • No resale registration statement planned for the notes or conversion shares

Item 8.01 · Other Events

  • Moderna announced a proposed offering on August 27, 2026, followed by pricing of the Notes on August 28, 2026
  • Debt issuance creates financing obligations and potential interest expense, with terms detailed in Exhibits 99.1 and 99.2
  • Anticipated use of proceeds is forward-looking and subject to execution, operating needs, and disclosed risk factors
  • Investors should review Exhibits 99.1 and 99.2 for offering size, pricing, maturity, interest rate, and proceeds allocation

Item EX-99.1 · Exhibit EX-99.1

  • Proposed $2.0B convertible senior notes due 2032, with initial purchasers’ option for an additional $300M
  • Zero regular interest and no principal accretion, limiting near-term cash interest expense
  • Proceeds targeted toward oncology investment, debt repayment, and capped-call transaction costs
  • Convertible settlement may include cash, Moderna shares, or both, creating potential equity dilution
  • Capped-call hedge targets dilution offset up to a cap initially at least 150% above pricing-date stock price

Item EX-99.2 · Exhibit EX-99.2

  • $2.6B upsized convertible notes due 2032, providing substantial funding for oncology investment and debt repayment
  • 0.00% coupon, approximately $2.563B net proceeds after fees and capped-call costs
  • Initial conversion price $210.58, a 47.5% premium to Moderna’s $142.77 share price
  • Approximately $285.0M capped-call cost, with a $392.6175 cap price intended to reduce conversion dilution
  • Potential future dilution remains, with additional $400.0M notes available under the initial purchasers’ option

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Moderna 8-K filings

Get the next MRNA 8-K as it lands

Follow MRNA for push alerts, or ask the research agent what this filing means.